Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Cannabinoid patent detail

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jul 12, 2022 1:56am

180 Views

Post# 34817122

RE:RE:Cannabinoid patent detail

Pandora wrote:

Pandora wrote: The patent application that is going through for the cannabinoid process seems to have got hung up on technicalities where the "Examiner" rejected it on the basis that he felt the evidence was not "persuasive" enough. Dr. Arkady Mandel wrote a rebuttal to further explain the interactions of the drugs. It is back to the Examiner with a request for further examination as of June 25, 2022.
I have had trouble trying to copy and paste their documents but, on this, I have tried pasting the overall link. I think it may work. Dr. Mandel's write up is quite good. Here goes: (8 pages - toggle at top of page)

https://portal.uspto.gov/pair/view/BrowsePdfServlet?objectId=L4T9POK8XBLUEX1&lang=DINO

We will have to wait for the next round of USPTO posting but at the moment based on an update from July 2nd it looks on the surface as though the Examiner did not accept Dr. Mandel's new documents as being persuasive enough either. It could take some time for the next posting. Final rejection does not often always end up being final.

Transaction History

Date Transaction Description

07-02-2022 Final Rejection

06-24-2022 Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received

Date	Transaction Description
07-02-2022	Final Rejection
06-24-2022	Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received

Well the USPTO examiner has issued the follow up dialogue supporting his "Final Rejection". It is a 20 page document but I believe the meat of it is in the Pages 3 - 6. I would have trouble doing an interpretation but maybe someone like Eoganacht can do it more justice than I,

https://portal.uspto.gov/pair/view/BrowsePdfServlet?objectId=L5B4NOXRGREENX5&lang=DINO

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market